Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Fleury sur Orne, France Clinical Trials

A listing of Fleury sur Orne, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (55) clinical trials

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

This is a multicenter and open-label (participants and researchers are aware of the treatment that participants are receiving) study that consists of 4 phases; a Prescreening Phase for biomarker evaluation only, a Screening Phase, a Treatment Phase (Cycle 1 Day 1 and will continue until the study drug is discontinued), ...

Phase

3.02 miles

Learn More »

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts: relapsed/refractory follicular lymphoma (FL) patients relapsed/refractory aggressive (DLBCL) lymphoma patients relapsed/refractory other indolent (iNHL) ...

Phase

3.02 miles

Learn More »

Study on Androgen Receptor and Triple Negative Breast Cancer

This is a multicenter uncontrolled, open-label, prospective, non-comparative randomized, phase II study. Patients will be randomized between darolutamide in Arm n1 (two-stage Simon's design) and capecitabine in Arm n2 with two patients randomized in Arm n1 for one patient randomized in Arm n2. The trial population is composed of women ...

Phase

3.02 miles

Learn More »

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

The present study will be carried out in patients suffering from refractory metastatic Renal Cell Carcinoma. The overall study population consists of 450 adult patients. In France, 10600 patients were diagnosed with kidney cancer in 2010. At the time of their diagnosis, approximately 30% of patients present with metastatic disease, ...

Phase

3.14 miles

Learn More »

Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy Safety and Quality of Life

Anal canal carcinoma (ACC) represents 1.2% of digestive cancers. Its incidence is increasing. As epidermoid ACC (95% of ACC) are particularly sensitive to radio and chemotherapy, concomitant radio-chemotherapy is the standard treatment of locally advanced ACC, with proven efficacy on locoregional control, anal sphincter preservation, progression-free survival and complete response ...

Phase

3.14 miles

Learn More »

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

This study has two arms: Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment. Arm 2 (INC280 + nivolumab) is open and enrolling as planned.

Phase

3.14 miles

Learn More »

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Total or near-total thyroidectomy is the primary treatment for differentiated thyroid carcinoma. Postoperatively, DTC are treated with radioiodine (131I) and thyroid stimulating hormone (TSH) suppressive levothyroxine therapy. But 5% to 20% of patients with DTC develop distant metastases; some of them become refractory to 131I therapy. Targeted therapies have been ...

Phase

3.14 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

Phase

3.14 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.

Phase

3.14 miles

Learn More »

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

OBJECTIVES: Primary - To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary - To evaluate the safety of this drug in these patients. - To determine time-to-event variables of overall survival, time to disease progression, time ...

Phase

3.14 miles

Learn More »